CompletedNot Applicable

Evaluating of the Impact of a Connected and Non-intrusive Device in Improving the Screening of Sleep Apnea Syndrome and the Addressing of Potentially Pathological Patients in Hospital Environment

France600 participantsStarted 2023-11-30

Plain-language summary

Diabetes, obesity and metabolic syndrome are closely linked to sleep apnea syndrome. Indeed, diabetic and/or obese patients present an increased risk of sleep apnoea syndrome (SAS), with a prevalence estimated at between 10 and 22%, depending on the study, and most of them requiring treatment with Continuous Positive Airway Pressure (CPAP). In this sub-population of patients, only between 40% and 50% benefit from CPAP.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult patients over 18 years old * Diabetes Mellitus (Type 1 or 2), or obesity (BMI\>30kg/m²) or metabolic syndrome * Hospitalized for at least one night in the Endocrinology department * Affiliated or entitled to a social security scheme * Having received informed information about the study and having co-signed, with the investigator, the informed consent form for participation in the study Exclusion Criteria: * Known and/or treated OSAS-type respiratory pathology * No signature of the informed consent form * Minor or adult patients under guardianship or curatorship

What they're measuring

patients real positive for each screening technique

Timeframe: Day 2

Trial details

NCT IDNCT06141967

SponsorCentre Hospitalier Universitaire de Saint Etienne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-02-19

View on ClinicalTrials.gov More Sleep Apnea Syndromes trials